Compare Stocks: IMMX, VKTX, RCUS, and TNGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMMX Immix Biopharma	$13.91 +0.6%	$11.03	$1.94 ▼ $15.10	$995.11M	0.2	1.52 million shs	1.05 million shs
RCUS Arcus Biosciences	$29.67 -1.5%	$29.21	$11.04 ▼ $31.74	$3.78B	0.81	1.10 million shs	736,980 shs
TNGX Tango Therapeutics	$22.52 -1.1%	$27.05	$6.25 ▼ $34.39	$3.80B	1.12	2.07 million shs	1.46 million shs
VKTX Viking Therapeutics	$34.87 +2.6%	$35.41	$22.96 ▼ $43.15	$4.07B	0.69	1.75 million shs	1.40 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMMX Immix Biopharma	0.00%	-0.22%	+38.27%	+75.41%	+526.58%
RCUS Arcus Biosciences	0.00%	+1.37%	+5.10%	+28.14%	+154.94%
TNGX Tango Therapeutics	0.00%	-3.51%	-22.34%	+11.37%	+236.12%
VKTX Viking Therapeutics	0.00%	+8.43%	+4.71%	+22.57%	+29.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMMX Immix Biopharma	$13.91 +0.6%	$11.03	$1.94 ▼ $15.10	$995.11M	0.2	1.52 million shs	1.05 million shs
RCUS Arcus Biosciences	$29.67 -1.5%	$29.21	$11.04 ▼ $31.74	$3.78B	0.81	1.10 million shs	736,980 shs
TNGX Tango Therapeutics	$22.52 -1.1%	$27.05	$6.25 ▼ $34.39	$3.80B	1.12	2.07 million shs	1.46 million shs
VKTX Viking Therapeutics	$34.87 +2.6%	$35.41	$22.96 ▼ $43.15	$4.07B	0.69	1.75 million shs	1.40 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMMX Immix Biopharma	0.00%	-0.22%	+38.27%	+75.41%	+526.58%
RCUS Arcus Biosciences	0.00%	+1.37%	+5.10%	+28.14%	+154.94%
TNGX Tango Therapeutics	0.00%	-3.51%	-22.34%	+11.37%	+236.12%
VKTX Viking Therapeutics	0.00%	+8.43%	+4.71%	+22.57%	+29.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMMX Immix Biopharma	2.78	Moderate Buy	$21.29	53.02% Upside
RCUS Arcus Biosciences	2.58	Moderate Buy	$37.80	27.40% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	92.99% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$96.63	177.10% Upside

Current Analyst Ratings Breakdown

Latest IMMX, VKTX, RCUS, and TNGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$66.00 ➝ $68.00
8/18/2026	VKTX Viking Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	IMMX Immix Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/12/2026	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $35.00
8/11/2026	TNGX Tango Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	IMMX Immix Biopharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $19.00
8/11/2026	VKTX Viking Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$75.00 ➝ $65.00
8/10/2026	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$23.00
8/10/2026	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $25.00
8/7/2026	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
8/6/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$41.00 ➝ $43.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$1.77 per share	N/A
RCUS Arcus Biosciences	$247M	15.30	N/A	N/A	$5.84 per share	5.08
TNGX Tango Therapeutics	$62.38M	60.87	N/A	N/A	$2.57 per share	8.76
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMMX Immix Biopharma	-$29.44M	-$0.88	N/A	N/A	N/A	N/A	-38.44%	-34.72%	11/6/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest IMMX, VKTX, RCUS, and TNGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/7/2026	Q2 2026	IMMX Immix Biopharma	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMMX Immix Biopharma	N/A	25.13	25.13
RCUS Arcus Biosciences	0.22	3.82	3.82
TNGX Tango Therapeutics	N/A	50.82	50.82
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMMX Immix Biopharma	11.26%
RCUS Arcus Biosciences	92.89%
TNGX Tango Therapeutics	78.99%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
IMMX Immix Biopharma	30.30%
RCUS Arcus Biosciences	7.60%
TNGX Tango Therapeutics	6.50%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMMX Immix Biopharma	9	71.54 million	49.86 million	Optionable
RCUS Arcus Biosciences	500	127.33 million	117.66 million	Optionable
TNGX Tango Therapeutics	90	168.61 million	157.65 million	Optionable
VKTX Viking Therapeutics	20	116.65 million	110.47 million	Optionable

IMMX, VKTX, RCUS, and TNGX Headlines

Recent News About These Companies

Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.

September 5 at 8:00 PM | fool.com

Odyssean LLC Boosts Stake in Viking Therapeutics, Inc. $VKTX

September 5 at 4:40 AM | marketbeat.com

The Manufacturers Life Insurance Company Takes $1.26 Million Position in Viking Therapeutics, Inc. $VKTX

September 5 at 4:39 AM | marketbeat.com

Concurrent Investment Advisors LLC Has $11.95 Million Stock Holdings in Viking Therapeutics, Inc. $VKTX

September 5 at 3:53 AM | marketbeat.com

Legal & General Group Plc Buys New Shares in Viking Therapeutics, Inc. $VKTX

September 5 at 3:43 AM | marketbeat.com

Is Viking Therapeutics (VKTX) Stock Fully Priced After A 411% Run?

September 4 at 8:35 PM | finance.yahoo.com

Jupiter Topco LLC Makes New Investment in Viking Therapeutics, Inc. $VKTX

September 4 at 3:43 AM | marketbeat.com

AXQ Capital LP Buys 56,796 Shares of Viking Therapeutics, Inc. $VKTX

September 4 at 3:19 AM | marketbeat.com

3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong

September 3 at 7:57 PM | fool.com

Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

September 3 at 7:57 PM | finance.yahoo.com

Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

September 3 at 6:46 PM | zacks.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

September 2, 2026 | finance.yahoo.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

September 2, 2026 | prnewswire.com

Quantitative Investment Management LLC Invests $1.61 Million in Viking Therapeutics, Inc. $VKTX

September 1, 2026 | marketbeat.com

Bank of New York Mellon Corp Takes Position in Viking Therapeutics, Inc. $VKTX

September 1, 2026 | marketbeat.com

VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3

August 31, 2026 | stocktwits.comS

Viking Therapeutics Is Down 66% — Here’s What Could Bring It Back

August 31, 2026 | nai500.comN

Viking Therapeutics Is Down 66% — Here’s What Could Bring It Back

August 31, 2026 | nai500.comN

Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Rating of "Moderate Buy" from Analysts

August 31, 2026 | americanbankingnews.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 31, 2026 | marketbeat.com

Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.

August 30, 2026 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, VKTX, RCUS, and TNGX Company Descriptions

Immix Biopharma NASDAQ:IMMX

$13.91 +0.08 (+0.58%)

As of 09/4/2026 04:00 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Arcus Biosciences NYSE:RCUS

$29.67 -0.46 (-1.53%)

As of 09/4/2026 03:58 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Tango Therapeutics NASDAQ:TNGX

$22.52 -0.24 (-1.05%)

As of 09/4/2026 04:00 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$34.87 +0.89 (+2.62%)

As of 09/4/2026 04:00 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMMX, VKTX, RCUS, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMMX, VKTX, RCUS, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMMX, VKTX, RCUS, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, VKTX, RCUS, and TNGX Company Descriptions

Immix Biopharma NASDAQ:IMMX

Arcus Biosciences NYSE:RCUS

Tango Therapeutics NASDAQ:TNGX

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMMX, VKTX, RCUS, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMMX, VKTX, RCUS, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMMX, VKTX, RCUS, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, VKTX, RCUS, and TNGX Company Descriptions

Immix Biopharma NASDAQ:IMMX

Arcus Biosciences NYSE:RCUS

Tango Therapeutics NASDAQ:TNGX

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools